Product Data Sheet

Product Name:	Tigecycline tetramesylate
Cat. No.:	GC37789

Chemical Properties

Cas. No.			
SMILES	O=S(C)(O)=O.O=S(C)(O)=O.O=S(C)(O)=O.O=C(C(C1=O)=C(O)[C@@H](N(C)C)[C@]2([H])C[C@]3([H])CC4=C(C(C3=C(O)[C@@]21O)=O)C(O)=C(NC(CNC(C)(C)C)=O)C=C4N(C)C)N.O=S(C)(O)=O		
Formula	$C_{33}H_{55}N_5O_{20}S_4$	M.Wt	970.07
Solubility	DMSO: 100 mg/mL (103.09 mM); Water: 50 mg/mL (51.54 mM)	Storage	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure	Tigecycline tetramesylate		

Background

Tigecycline is a broad-spectrum glycylcycline antibiotic that binds to the bacterial 30S ribosome, blocking the entry of transfer RNA, which halts protein synthesis and inhibits bacterial growth.[1] It is active against a panel of 1,924 European clinical bacterial isolates including *S. aureus, S. epidermidis, S. pneumoniae, E. faecalis, E. faecium, E. coli, K. pneumoniae, P. aeruginosa*, and *P. mirabilis* strains (MICs = <1-32 µg/ml).[2] *In vivo*, tigecycline (6.25 mg/kg twice daily for 5 days) decreases levels of *C. difficile* cytotoxin activity and spore formation in cecum and colon in a mouse model of *C. difficile* infection.[3] Formulations containing tigecycline have been used in the treatment of a variety of bacterial infections.

1.Greer, N.D.Tigecycline (Tygacil): The first in the glycylcycline class of antibioticsProc. (Bayl. Univ. Med. Cent.)19(2)155-161(2006) 2.Milatovic, D., Schmitz, F.J., Verhoef, J., et al.Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

clinical bacterial isolatesAntimicrob. Agents Chemother.47(1)400-404(2003) 3.Theriot, C.M., Schumacher, C.A., Bassis, C.M., et al.Effects of tigecycline and vancomycin administration on established Clostridium difficile infectionAntimicrob. Agents Chemother.59(3)1596-1604(2015)

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA